By Devika Patel
Knoxville, Tenn., Nov. 25 - ReGen Therapeutics plc said it arranged a £2 million committed equity financing facility with Duke Holdings Corp. Ltd.
Duke subscribed for 350,000 new ordinary shares at 5.5p per share on Nov. 4.
Proceeds will be used as working capital.
ReGen Therapeutics is a London biotechnology company.
| Issuer: | ReGen Therapeutics plc
|
| Issue: | Committed equity financing facility
|
| Amount: | £2 million
|
| Warrants: | No
|
| Investor: | Duke Holdings Corp. Ltd.
|
| Announcement date: | Nov. 25
|
| Settlement date: | Nov. 4 (for £19,250)
|
| Stock symbol: | London: RGT
|
| Stock price: | 8.75p at close Nov. 4
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
